The pathogenesis of rosacea is multifactorial; however, this paper will focus on the pivotal role of interleukin 17 (IL-17) in the development and progression of the disease.
Th2 pathway inhibition by dupilumab may promote <i>Demodex</i> proliferation and increased IL-17-mediated inflammation implicated in the pathophysiology of rosacea.